Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification

Bibliography

• Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275–1281.
   PubMed Web of Science ®Google Scholar
• Holohan C, Schaeybroeck SV. Longley DB and Johnston PG. Cancer drug resistance: an evolving paradigm. Nature. 2013;13:714–724.
   Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. Clin Invest. 2011;121(7):2750–2767. DOI:10.1172/JCI45014.
   Google Scholar
• The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumors. Nature. 2012;490(7418):61–70. DOI:10.1038/nature11412.
   PubMed Web of Science ®Google Scholar
• Balko JM, Giltnane JM, Wang K. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4(2):232–245. DOI:10.1158/2159-8290.CD-13-0286.
   PubMed Web of Science ®Google Scholar
• Montagna E, Maisonneuve P, Rotmensz N, et al. Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome. Clin Breast Cancer. 2013;13:31–39.
   PubMed Web of Science ®Google Scholar
• Masuda H, Baggerly KA, Wang Y, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19(19):5533–5540.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Helleday T, Petermann E, Lundin C, et al. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008;8:193–204.
   PubMed Web of Science ®Google Scholar
• Hühn D, Bolck HA, Sartori AA. Targeting DNA double-strand break signalling and repair: recent advances in cancer therapy. Swiss Med Wkly. 2013;143:w13837.
   PubMed Web of Science ®Google Scholar
• Rodriguez A, Makris A, Wu MF, et al. DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. Breast Cancer Res Treat. 2010;123:189–196.
   PubMed Web of Science ®Google Scholar
• Ha K, Fiskus W, Choi DS, et al. Histone deacetylase inhibitor treatment induces ‘BRCAness’ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget. 2014;5(14):5637–5650.
   PubMed Web of Science ®Google Scholar
• Minotti G, Menna P, Salvatorelli E, et al. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56:185–229.
   PubMed Web of Science ®Google Scholar
• Mrklić I, Pogorelić Z, Ćapkun V, et al. Expression of topoisomerase II-α in triple negative breast cancer. Appl Immunohistochem Mol Morphol. 2014;22(3):182–187. DOI:10.1097/PAI.0b013e3182910967.
   PubMedGoogle Scholar
• Von Minckwitz G, Muller BM, Loibl S, et al. Cytoplasmic poly (adenosine diphosphate–ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy. J Clin Oncol. 2011;29:2150–2157.
   PubMed Web of Science ®Google Scholar
• Anders CK, Winer EP, Ford JM, et al. PARP inhibition: “targeted” therapy for triple negative breast cancer. Clin Cancer Res. 2010;16(19):4702–4710.
   PubMed Web of Science ®Google Scholar
• Tutt A, Robson M, Garber JE, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235–244.
   PubMed Web of Science ®Google Scholar
• Isakoff SJ, Overmoyer B, Tung NM, et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol. 2010;28(15 Suppl.):abstract 1019.
   Google Scholar
• Ibrahim YH, García-García C, Serra V, et al. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov. 2012;2:1036–1047.
   PubMed Web of Science ®Google Scholar
• Juvekar A, Burga LN, Hu H, et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2012;2(11):1048–1063.
   PubMed Web of Science ®Google Scholar
• Tian M, Zhong Y, Zhou F, et al. Platinum-based therapy for triple-negative breast cancer treatment: a meta-analysis. Mol Clin Oncol. 2015;3:720–724.
   PubMedGoogle Scholar
• Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer. J Clin Oncol. 2010;28:1145–1153.
   PubMed Web of Science ®Google Scholar
• Ozkan C, Gumuskaya B, Yaman S, et al. ERCC1 expression in TNBC. J Buon. 2012;17:271–276.
   PubMed Web of Science ®Google Scholar
• O’Reilly EA, Gubbins L, Sharma S. The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clinical. 2015;3:257–275.
   PubMed Web of Science ®Google Scholar
• Ossovskaya V, Wang Y, Budoff A. Exploring molecular pathways of triple-negative breast cancer. Genes Cancer. 2011;2(9):870–879.
   PubMedGoogle Scholar
• Zhou FF, Yan M, Guo GF, et al. Knockdown of eIF4E suppresses cell growth and migration, enhances chemosensitivity and correlates with increase in Bax/Bcl-2 ratio in triple-negative breast cancer cells. Med Oncol. 2011;28:1302–1307.
   PubMed Web of Science ®Google Scholar
• Caldas-Lopes E, Cerchietti L, Ahn JH, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. PNAS. 2009 19;106(20):8368–8373.
   PubMed Web of Science ®Google Scholar
• Mataga MA, Rosenthal S, Heerboth S, et al. Anti-breast cancer effects of histone deacetylase inhibitors and calpain inhibitor. Anticancer Res. 2012;32:2523–2530.
   PubMed Web of Science ®Google Scholar
• Rao R, Balusu R, Fiskus W, et al. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells. Mol Cancer Ther. 2012;11(4):973–983.
   PubMed Web of Science ®Google Scholar
• Librizzi M, Longo A, Chiarelli R, et al. Cytotoxic effects of Jay Amin hydroxamic acid (JAHA), a ferrocene-based class I histone deacetylase inhibitor, on triple-negative MDAMB231 breast cancer cells. Chem Res Toxicol. 2012;25:2608–2616.
   PubMed Web of Science ®Google Scholar
• Tate CR, Rhodes LV, Segar HC, et al. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 2012;14:R79.
   PubMed Web of Science ®Google Scholar
• Palmieri D, Lockman PR, Thomas FC, et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res. 2009;15(19):6148–6157.
   PubMed Web of Science ®Google Scholar
• Rhodes LV, Tate CR, Segar HC, et al. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Breast Cancer Res Treat. 2014;145:593–604.
   PubMed Web of Science ®Google Scholar
• Robinson TJW, Liu JC, Vizeacoumar F. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS One. 2013;8(11):e78641. DOI:10.1371/journal.pone.0078641.
   PubMed Web of Science ®Google Scholar
• McClendon AK, Jeffry LD, Rivadeneira DB, et al. CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy. Cell Cycle. 2012;11(14):2747–2755.
   PubMed Web of Science ®Google Scholar
• Horiuchi D, Kusdra L, Huskey NE, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med. 2012;209(4):679–696.
   PubMed Web of Science ®Google Scholar
• Gasparini P, Fassan M, Cascione L, et al. Androgen receptor status is a prognostic marker in non-basal triple negative breast cancers and determines novel therapeutic options. PLoS One. 2014;9(2):e88525. DOI:10.1371/journal.pone.0088525.
   PubMedGoogle Scholar
• Murray S, Briasoulis E, Linardou H, et al. Mechanisms of taxane resistance in breast cancer: a systematic review. MOJ. 2011;1:14–29.
   Google Scholar
• Thomas ES, Gomez HL, Li RK, et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007;25:5210–5217.
   PubMed Web of Science ®Google Scholar
• Al-Ejeh F, Simpson PT, Saunus JM, et al. Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. Oncogenesis. 2014;3:e124. DOI:10.1038/oncsis.2014.41.
   PubMed Web of Science ®Google Scholar
• Maia ARR, De Man J, Boon U. Inhibition of the spindle assembly checkpoint kinase TTK enhances the efficacy of docetaxel in a triple-negative breast cancer model. Ann Oncol. 2015;1–13. DOI:10.1093/annonc/mdv293.
   Web of Science ®Google Scholar
• Varna M, Bousquet G, Plassa LF, et al. TP53 status and response to treatment in breast cancers. J Biomed Biotechnol. 2011;Article ID 284584:9 p.
   Google Scholar
• Ma CX, Cai S, Li S, et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest. 2012;122(4):1541–1552.
   PubMed Web of Science ®Google Scholar
• Kim T, Han W, Kim MK, et al. Predictive significance of p53, Ki-67, and Bcl-2 expression for pathologic complete response after neoadjuvant chemotherapy for triple-negative breast cancer. Breast Cancer. 2015;18(1):16–21.
   Web of Science ®Google Scholar
• Lehmann-Che J, André F, Desmedt C, et al. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers. Oncologist. 2010;15:246–252.
   PubMed Web of Science ®Google Scholar
• Alco G, Bozdogan A, Selamoglu D, et al. Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients. Oncol Lett. 2015;9:1046–1054.
   PubMed Web of Science ®Google Scholar
• Tan QX, Qin QH, Yang WP, et al. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. Int J Clin Exp Pathol. 2014;7(10):6862–6870.
   PubMed Web of Science ®Google Scholar
• Li H, Han X, Liu Y, et al. Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancer. Oncol Lett. 2015;9:149–152.
   PubMed Web of Science ®Google Scholar
• Tökés A-M, Szász AM, Geszti F, et al. Expression of proliferation markers Ki67, cyclin A, geminin and aurora-kinase A in primary breast carcinomas and corresponding distant metastases. J Clin Pathol. 2015;1–9. DOI:10.1136/jclinpath-2014-202607.
   Web of Science ®Google Scholar
• Blanchard Z, Mullins N, Ellipeddi P, et al. Overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative. PLoS One. 2014;9(4):e95663.
   Google Scholar
• Di Bonito M, Cantile M, Collina F, et al. Overexpression of cell cycle progression inhibitor geminin is associated with tumor stem-like phenotype of triple-negative breast cancer. J Breast Cancer. 2012;15(2):162–171.
   PubMed Web of Science ®Google Scholar
• Flynn JF, Wong C, Jm W. Anti-EGFR therapy: mechanism and advances in clinical efficacy in breast cancer. J Oncol. 2009;Article ID 526963:16 p.
   Google Scholar
• Cho EY, Chang MH, Choi YL, et al. Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC). Cancer Chemother Pharmacol. 2011;68:753–761.
   PubMed Web of Science ®Google Scholar
• Nogi H, Kobayashi T, Suzuki M, et al. EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. Oncol Rep. 2009;21:413–417.
   PubMed Web of Science ®Google Scholar
• Tang Y, Zhu L, Li Y, et al. Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer. J Transl Med. 2012;10(Suppl 1):S4.
   PubMedGoogle Scholar
• Masuda H, Zhang D, Bartholomeusz C, et al. Role of epidermal growth factor receptor in breast cancer. Breast Cancer Res Treat. 2012;136(2). DOI:10.1007/s10549-012-2289-9.
   PubMed Web of Science ®Google Scholar
• Sohn J, Liu S, Parinyanitikul N, et al. cMET activation and EGFR-directed therapy resistance in triple-negative breast cancer. J Cancer. 2014;5(9):745–753.
   PubMed Web of Science ®Google Scholar
• Carey LA, Rugo HS, Marcom PK, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30(21):2615–2623.
   PubMed Web of Science ®Google Scholar
• Baselga J, Gomez P, Greil R, et al. Randomized phase II study of the anti–epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. J Clin Oncol. 2013;31(20):2586–2592.
   PubMed Web of Science ®Google Scholar
• Al-Ejeh F, Wei S, Mariska M. Treatment of triple-negative breast cancer using anti-EGFR–directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor. J Nucl Med. 2013;54:913–921.
   PubMed Web of Science ®Google Scholar
• Sun T, Aceto N, Meerbrey KL, et al. Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell. 2011;144:703–718.
   PubMed Web of Science ®Google Scholar
• Malin D, Strekalova E, Petrovic V, et al. αB-crystallin: a novel regulator of breast cancer metastasis to the brain. Clin Cancer Res. 2014;20(1):56–67.
   PubMed Web of Science ®Google Scholar
• Yi YW, Hong W, Kang HJ, et al. Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells. J Cell Mol Med. 2013;175:648–656.
   Web of Science ®Google Scholar
• Inanc M, Ozkan M, Karaca H, et al. Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Med Oncol. 2014;31:801.
   PubMed Web of Science ®Google Scholar
• Zagouri F, Bago-Horvath Z, Rossler F, et al. High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer. Br J Cancer. 2013; 108:1100–1105.
   PubMed Web of Science ®Google Scholar
• Kim YJ, Jong-Sun C, Seo J, et al. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer. Int J Cancer. 2014;134:2424–2436.
   PubMed Web of Science ®Google Scholar
• Jansson S, Bendah PO, Dorthe AG, et al. The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRa, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer. PLoS One. 2014;9(7):e102176. DOI:10.1371/journal.pone.0102176.
   Google Scholar
• Polivka J, Janku F. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway. Pharmacol Ther. 2014;142(2):164–175.
   PubMed Web of Science ®Google Scholar
• Kriegsmann M, Endris V, Wolf T, et al. Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences. Oncotarget. 2014;5(20):9952–9965.
   PubMed Web of Science ®Google Scholar
• Singh JC, Novik Y, Stein S, et al. Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer. Breast Cancer Res. 2014;16:R32.
   PubMed Web of Science ®Google Scholar
• Liu JC, Voisin V, Wang S, et al. Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. EMBO Mol Med. 2014;6:1542–1560.
   PubMed Web of Science ®Google Scholar
• Tryfonopoulos D, Walsh S, Collins DM, et al. Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol. 2011;22:2234–2240.
   PubMed Web of Science ®Google Scholar
• Ortiz-Ruiz MJ, Alvarez-Fernandez S, Parrott T, et al. Therapeutic potential of ERK5 targeting in triple negative breast cancer. Oncotarget. 2014;5(22):11308–11318.
   PubMed Web of Science ®Google Scholar
• Al-Ejeh F, Miranda M, Shi W, et al. Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer. Oncotarget. 2014;5(10):3145–3158.
   PubMed Web of Science ®Google Scholar
• Pistelli M, Caramanti M, Biscotti T, et al. Androgen receptor expression in early triple-negative breast cancer: clinical significance and prognostic associations. Cancers. 2014;6:1351–1362.
   PubMedGoogle Scholar
• McGhan LJ, McCullough AE, Protheroe CA, et al. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol. 2014;21:361–367.
   PubMed Web of Science ®Google Scholar
• Mrklić I, Pogorelić Z, Ćapkun V, et al. Expression of androgen receptors in triple negative breast carcinomas. Acta Histochemica. 2013;115(4):344–348.
   PubMed Web of Science ®Google Scholar
• McNamara KM, Yoda T, Miki Y, et al. Androgenic pathway in triple negative invasive ductal tumors: its correlation with tumor cell proliferation. Cancer Sci. 2013;104:639–346.
   PubMed Web of Science ®Google Scholar
• Thike AA, Chong YZ, Cheok PY, et al. Loss of androgen receptor expression predicts early recurrence in triple negative and basal-like breast cancer. Mod Pathol. 2014;27:352–360.
   PubMed Web of Science ®Google Scholar
• Shapiro DJ, Mao C, Cherian MT. Small molecule inhibitors as probes for estrogen and androgen receptor action. J Biol Chem. 2011;286(6):4043–4048.
   PubMed Web of Science ®Google Scholar
• Lehmann BD, Bauer JA, Schafer JM, et al. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014;16:406.
   PubMed Web of Science ®Google Scholar
• Cuenca-López MD, Montero JC, Morales JC, et al. Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling. BMC Cancer. 2014;14:302.
   PubMed Web of Science ®Google Scholar
• Koletsa T, Stavridi F, Bobos M, et al. αB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies. BMC Clin Pathol. 2014;14:28.
   PubMedGoogle Scholar
• Umemura S, Shirane M, Takekoshi S, et al. High expression of thymidine phosphorylase in basal-like breast cancers: stromal expression in EGFR-and/or CK5/6-positive breast cancers. Oncol Lett. 2010;1:261–266.
   PubMed Web of Science ®Google Scholar
• Abdel-Fatah TMA, Perry C, Dickinson P, et al. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Ann Oncol. 2013;24:2801–2807.
   PubMed Web of Science ®Google Scholar
• Bouchalova K, Kharaishvili G, Bouchal J, et al. Triple negative breast cancer - BCL2 in prognosis and prediction. Rev Curr Drug Targets. 2014;15:1166–1175.l2.
   PubMed Web of Science ®Google Scholar
• Alikanoglu AS, Yildirim M, Suren D, et al. Expression of cyclooxygenase-2 and Bcl-2 in breast cancer and their relationship with triple-negative disease. J Buon. 2014;19(2):430–434.
   PubMed Web of Science ®Google Scholar
• Zhou L, Li K, Luo Y, et al. Novel prognostic markers for patients with triple-negative breast cancer. Hum Pathol. 2013;44:2180–2187.
   PubMed Web of Science ®Google Scholar
• Rahman M, Davis SR, Pumphrey JG, et al. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype. Breast Cancer Res Treat. 2009;113(2):217–230. DOI:10.1007/s10549-008-9924-5. Epub 2008 Feb 12.
   PubMed Web of Science ®Google Scholar
• Huck B, Duss S, Hausser A, et al. Elevated protein kinase D3 (PKD3) expression supports proliferation of triple-negative breast cancer cells and contributes to mTORC1-S6K1 pathway activation. J Biol Chem. 2014;289(6):3138–3147.
   PubMed Web of Science ®Google Scholar
• Luo R-Z, Yuan Z-Y, Li M, et al. Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer. Onco Targets Ther. 2013;6:883–888.
   PubMedGoogle Scholar
• Chen S, Jiang YZ, Huang L, et al. The residual tumor autophagy marker LC3B serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy. Clin Cancer Res. 2013;15(19):6853–6862.
   Web of Science ®Google Scholar
• Stagg J, Allard B. Immunotherapeutic approaches in triple negative breast cancer: latest research and clinical prospects. Ther Adv Med Oncol. 2013;5(3):169–181.
   PubMed Web of Science ®Google Scholar
• Rathore AS, Goel MM, Makker A, et al. Prognostic impact of CD3 tumor infiltrating lymphocytes in triple-negative breast cancer. Indian J Clin Pract. 2013;24(4):376–380.
   Google Scholar
• Engel JB, Honig A, Kapp M, et al. Mechanisms of tumor immune escape in triple-negative breast cancers (TNBC) with and without mutated BRCA 1. Arch Gynecol Obstet. 2014;289:141–147.
   PubMed Web of Science ®Google Scholar
• Lopes LF, Guembarovski RL, Guembarovski AL, et al. FOXP3 transcription factor: a candidate marker for susceptibility and prognosis in triple negative breast cancer. Biomed Res Int. 2014;2014:Article ID 341654, 7 p.
   Google Scholar
• Dolan DE, Pharm D, Gupta S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control. 2014;21(3):231–237.
   PubMed Web of Science ®Google Scholar
• Huang O, Zhang W, Zhi Q, et al. Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells. Exp Biol Med. 2015;240:426–437.
   PubMed Web of Science ®Google Scholar
• Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. In: Proceedings of the 106th annual meeting of the american association for cancer research; 2015 Apr 18–22; Philadelphia, PA. Philadelphia (PA): AACR; 2015. Abstract nr {2859}.
   Google Scholar
• West NR, Milne K, Truong PT. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res. 2011;13:R126.
   PubMed Web of Science ®Google Scholar
• Allard B, Turcotte M, Stagg J. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. Expert Opin Ther Targets. 2014;18(8):863–881.
   PubMed Web of Science ®Google Scholar
• Loi S, Pommey S, Haibe-Kains B. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. PNAS. 2013;110(27):11091–11096.
   PubMed Web of Science ®Google Scholar
• Khaled W, Lee SC, Stingl J, et al. BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells. Nat Commun. 2015;6:5987. DOI:10.1038/ncomms6987.
   PubMed Web of Science ®Google Scholar
• Kolacinska A, Morawiec J, Fendler W, et al. Association of microRNAs and pathologic response to preoperative chemotherapy in triple negative breast cancer: preliminary report. Mol Biol Rep. 2014;41:2851–2857.
   PubMed Web of Science ®Google Scholar
• Dent R, Hanna WM, Trudeau M, et al. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009;115:423–428.
   PubMed Web of Science ®Google Scholar
• Bender RJ, Gabhann FM. Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancer. PLoS One. 2013;8(5):e61788. DOI:10.1371/journal.pone.0061788.
   PubMed Web of Science ®Google Scholar
• Gutwein LG, Al-Quran SZ, Fernando S, et al. Tumor endothelial marker 8 expression in triple-negative breast cancer. Anticancer Res. 2011;31:3417–3422.
   PubMed Web of Science ®Google Scholar
• Eccles SA, Aboagye EO, Ali S. Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Res. 2013;15:R92.
   PubMed Web of Science ®Google Scholar
• Aberasturi AL, Calvo A. TMPRSS4: an emerging potential therapeutic target in caner. Br J Cancer. 2014;1–5. DOI:10.1038/bjc.2014.403.
   Web of Science ®Google Scholar
• Cheng D, Kong H, Li Y. TMPRSS4 as a poor prognostic factor for triple-negative breast cancer. Int J Mol Sci. 2013;14:14659–14668.
   PubMed Web of Science ®Google Scholar
• Nakagawa M, Bando Y, Nagao T, et al. Expression of P53, Ki-67, E-Cadherin, N-Cadherin and Top2a in triple-negative breast cancer. Anticancer Res. 2011;31:2389–2394.
   PubMed Web of Science ®Google Scholar
• Kashiwagi S, Yashiro M, Takashima T, et al. Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at stage II: usefulness of prognostic markers E-cadherin and Ki67. Breast Cancer Res. 2011;13:R122.
   PubMed Web of Science ®Google Scholar
• Yu S, Wang X, Liu G, et al. High level of CXCR4 in triple-negative breast cancer specimens associated with a poor clinical outcome. Acta Med Okayama. 2013;67(6):369–375.
   PubMed Web of Science ®Google Scholar
• Ma F, Li H, Wang H, et al. Enriched CD44+/CD24− population drives the aggressive phenotypes presented in triple-negative breast cancer (TNBC). Cancer Lett. 2014;353:153–159.
   PubMed Web of Science ®Google Scholar
• Chen DR, Lu DY, Lin HY, et al. Mesenchymal stem cell-induced doxorubicin resistance in triple negative breast cancer. Biomed Res Int. 2014;2014:Article ID 532161, 10 p.
   Google Scholar
• Alamgeer M, Ganju V, Kumar B, et al. Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer. Breast Cancer Res. 2014;16:R44.
   Google Scholar
• Cancello G, Bagnardi V, Sangalli C, et al. Phase II study with epirubicin, cisplatin and infusional fluorouracil (ECF) followed by weekly paclitaxel plus metronomic cyclophosphamide as preoperative treatment of triple negative breast cancer. Clin Breast Cancer. 2015. DOI:10.1016/j.clbc.2015.03.002.
   Web of Science ®Google Scholar
• Gerber B, Loibl S, Eidtmann H, et al. Neoadjuvant bevacizumab and anthracycline–taxane-based chemotherapy in 678 triple-negative primary breast cancers; results from the geparquinto study (GBG 44). Ann Oncol. 2013;24:2978–2984.
   PubMed Web of Science ®Google Scholar